Core Viewpoint - Actimed Therapeutics has strengthened its global intellectual property position with the granting of a new composition of matter patent for S-pindolol benzoate (ACM-001.1) by the Japan Patent Office, enhancing its coverage in key pharmaceutical markets [1][2][3]. Intellectual Property Protection - The newly granted Japanese patent provides broad protection for S-pindolol benzoate and its pharmaceutically acceptable forms, extending coverage beyond prior patents and complementing existing patents in the US and Europe [2]. - This patent ensures long-term exclusivity for a wide range of potential clinical applications, including cancer cachexia and other muscle-wasting conditions [2][3]. Clinical Development - Actimed is progressing S-pindolol benzoate through clinical development, including the ongoing PROACT Phase 2a program, which investigates its potential to reduce muscle-wasting in obese patients when used in combination with a GLP-1 receptor agonist [3][8]. - Previous studies have shown promising Phase 2a proof of concept data in cancer cachexia patients, and early non-clinical data suggests a potential role for S-pindolol benzoate in preserving muscle mass during weight loss [8]. Company Overview - Actimed Therapeutics is a clinical-stage specialty pharmaceutical company focused on advancing muscle health in cancer cachexia, obesity, and other muscle-wasting disorders [5]. - The company also owns global rights to S-oxprenolol (ACM-002), which is being developed for muscle wasting in amyotrophic lateral sclerosis (ALS) and has received US Orphan Drug Designation for this indication [9].

Key Points Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing valuation. 10 stocks we like better than Pfizer › I can think of more than a few reasons why someone might want to invest in Pfizer (NYSE: PFE), the pharmaceutical giant. The best one, for me at the moment, is its huge dividend yield -- 7% as of Friday. Consider that the best high-yield bank s ...

Core Insights - AlphaQuest LLC increased its stake in Forte Biosciences by 300.7% in Q2, owning 16,897 shares valued at $218,000 [2] - Analysts have mixed ratings on Forte Biosciences, with a consensus rating of "Moderate Buy" and an average price target of $68.00 [3] - Forte Biosciences reported an EPS of ($0.96) for the last quarter, exceeding the consensus estimate of ($1.21) by $0.25 [5] Company Overview - Forte Biosciences is a biopharmaceutical company based in Dallas, Texas, focusing on developing treatments for autoimmune diseases [6] - The company is working on the FB-102 program, targeting conditions such as graft-versus-host disease, vitiligo, and alopecia areata [6] Stock Performance - Forte Biosciences shares opened at $12.94, with a market capitalization of $160.84 million and a P/E ratio of -1.88 [4] - The stock has experienced a 12-month low of $4.11 and a high of $28.68 [4]

Core Viewpoint - AlphaQuest LLC significantly reduced its stake in Intellia Therapeutics by 57.1% in Q2, indicating a shift in investment strategy towards the company [2] Institutional Holdings - Generali Investments Towarzystwo Funduszy Inwestycyjnych increased its position by 23.5%, now holding 100,000 shares valued at $938,000 after acquiring 19,000 shares [3] - D.A. Davidson & CO. raised its holdings by 108.0%, owning 54,120 shares worth $508,000 after purchasing 28,100 shares [3] - VIRGINIA RETIREMENT SYSTEMS ET Al established a new position valued at approximately $166,000 [3] - Harbour Investments Inc. increased its stake by 27.2%, now owning 6,633 shares valued at $62,000 after buying 1,419 shares [3] - CWM LLC grew its holdings by 22.9%, now owning 18,331 shares valued at $172,000 after acquiring 3,419 shares [3] - Institutional investors currently own 88.77% of Intellia Therapeutics' stock [3] Price Performance - Intellia Therapeutics' stock opened at $12.62, with a market capitalization of $1.35 billion and a PE ratio of -2.69 [4] - The stock has a 12-month low of $5.90 and a high of $28.25, with 50-day and 200-day moving averages at $17.12 and $12.38, respectively [4] Earnings Results - For the latest quarter, Intellia reported an EPS of ($0.99), beating the consensus estimate of ($1.03) by $0.04 [4] - Revenue for the quarter was $14.25 million, exceeding analyst estimates of $12.26 million, and reflecting a year-over-year increase of 104.3% [4] - The company had a negative return on equity of 57.48% and a negative net margin of 908.48% [4] Analyst Ratings - Robert W. Baird set a price target of $9.00 for Intellia Therapeutics [5] - Citigroup maintained a "market outperform" rating, while William Blair downgraded the stock from "outperform" to "market perform" [5] - Chardan Capital reduced its target price from $60.00 to $48.00, maintaining a "buy" rating [5] - The consensus rating for Intellia Therapeutics is "Hold" with an average price target of $23.74 [5] Insider Activity - Director William J. Chase acquired 100,000 shares at an average cost of $10.03, totaling $1,003,000, increasing his position by 288.24% [6] - CAO Michael P. Dube sold 1,871 shares at an average price of $17.38, resulting in a total transaction of $32,517.98, representing a 3.27% decrease in his ownership [7] - Insiders currently own 3.10% of the company's stock [7] Company Overview - Intellia Therapeutics focuses on genome editing and the development of curative therapeutics, with programs including NTLA-2001, NTLA-2002, and NTLA-3001 [8]

Institutional Investment Activity - Ameritas Advisory Services LLC acquired a new position in Upstart worth approximately $34,000 during the 2nd quarter [1] - GAMMA Investing LLC increased its position by 23.3% in the 1st quarter, now owning 1,662 shares valued at $77,000 after purchasing an additional 314 shares [1] - Bogart Wealth LLC grew its position by 140.0% in the 2nd quarter, now holding 1,200 shares worth $78,000 after acquiring 700 shares [1] - PNC Financial Services Group Inc. increased its position by 385.1% in the 1st quarter, now owning 1,950 shares valued at $90,000 after buying 1,548 shares [1] - NewEdge Advisors LLC lifted its holdings by 20.0% in the 1st quarter, now owning 1,997 shares worth $92,000 after acquiring 333 shares [1] - Institutional investors and hedge funds collectively own 63.01% of Upstart's stock [1] Analyst Ratings and Price Targets - Bank of America reduced its price target from $88.00 to $87.00, maintaining a "neutral" rating [2] - JPMorgan Chase & Co. upgraded its rating from "neutral" to "overweight," lowering the price target from $93.00 to $88.00 [2] - Goldman Sachs cut its price target from $78.00 to $54.00, assigning a "sell" rating [2] - Piper Sandler set a price target of $80.00 [2] - Morgan Stanley reaffirmed an "equal weight" rating [2] - The consensus rating for Upstart is "Hold" with a target price of $78.83 [2] Insider Trading Activity - CFO Sanjay Datta sold 13,473 shares at an average price of $61.12, totaling $823,469.76, reducing his ownership by 4.33% [3] - Director Kerry Whorton Cooper sold 500 shares at an average price of $69.21, totaling $34,605.00, representing a 1.93% decrease in ownership [3] - Insiders have sold 106,214 shares worth $6,803,558 over the last 90 days, with insiders owning 16.67% of the company's stock [3] Financial Performance - Upstart reported $0.36 EPS for the last quarter, exceeding the consensus estimate of $0.27 by $0.09 [5] - Revenue for the quarter was $257.29 million, surpassing the consensus estimate of $225.35 million, reflecting a year-over-year increase of 101.6% [5] - The company had a negative net margin of 0.75% and a negative return on equity of 5.95% [5] - Upstart's FY 2025 guidance includes EPS expectations, with analysts forecasting -0.03 EPS for the current year [5] Stock Performance and Market Metrics - Upstart shares opened at $47.52, with a market cap of $4.57 billion and a price-to-earnings ratio of -594.00 [4] - The stock has a beta of 2.27, indicating higher volatility compared to the market [4] - The 50-day simple moving average is $58.50, and the 200-day simple moving average is $59.96 [4] - The stock has experienced a one-year low of $31.40 and a one-year high of $96.43 [4]

AlphaQuest LLC grew its stake in Penumbra, Inc. (NYSE:PEN – Free Report) by 237.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 838 shares of the company’s stock after buying an additional 590 shares during the period. AlphaQuest LLC’s holdings in Penumbra were worth $215,000 at the end of the most recent reporting period. Get Penumbra alerts: A number of other hedge funds and other institut ...

Oppenheimer Asset Management Inc. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,568 shares of the biotechnology company’s stock, valued at approximately $245,000. Get Exelixis alerts: Other institutional investors and hedge funds have also made changes to their positions in the company. Belpointe Asset Management LLC purchased a new stake in shares of Exelixis d ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Key Points This ETF is on a stellar run in 2025, and more of the same could be in store next year. It provides exposure to a resurgent asset class, and that rebound is still in its infancy. It's cheap to own and holds thousands of stocks, highlighting a diverse portfolio. 10 stocks we like better than Vanguard FTSE Developed Markets ETF › One of the biggest themes playing out in stocks this year is the redemption story being penned by international equities, in both developed and emerging markets ...

InterDigital ( IDCC ) released 3Q25 earnings last Friday, and overall, I was quite impressed. They somewhat exceeded expectations with a Non-GAAP EPS of $2.55, which beat estimates by $0.50. Revenue also did well, coming in at $164.7 million, up 28% year-over-year and about $11.35 million aboveI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, a ...